Drug firm Takeda has moved over 250 San Diego-based employees into a new R&D center, adding to the company’s existing research centers in Boston and Kanagawa, outside Tokyo.
The site lead, David Weitz, noted that the research center is the result of Takeda’s growth and acquisitions, starting with its 2005 acquisition of Syrrx, a Berkeley Lab startup. Syrrx developed Berkeley Lab X-ray crystallography technology supporting targeted drug development.
“We’ve transitioned from being a site of discrete origin to being a true melting pot,” says Weitz, who is also a former employee of Syrrx.